Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03937921 · ClinicalTrials.gov registry record

Dotarem Evaluation for Myocardial Perfusion CMR

A clinical trial, sponsored by Medical University of South Carolina.

Completed
Registry status
90
Enrollment target

NCT03937921 is a clinical trial that has completed, run by Medical University of South Carolina. The registered enrollment target is 90 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03937921 has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
90 participants
Enrollment target

Study Summary

The overall goal of this study is to investigate the signal intensity and relaxation rate characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol (Gadavist) to prove that Dotarem provides constantly high myocardial relaxation necessary for accurate quantitative perfusion evaluation. The purpose of this study is to compare two types of contrast that patients receive during cardiac MRI scans to visualize the blood flow in the cardiac muscle. Both contrasts are used in standard of care procedures, and the one administered for each patient will be randomly selected. The length of the MRI study all procedures are the same as the clinically indicated scan.

Interventions

  • DRUG Gadavist 15Ml Solution for Injection

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2019-07-03
Est. Completion 2024-10-31

What the Registry Record Tells You About NCT03937921

The ClinicalTrials.gov registry entry for NCT03937921 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Gadavist 15Ml Solution for Injection is the first listed.

NCT03937921 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03937921 about?

NCT03937921 is a clinical study titled "Dotarem Evaluation for Myocardial Perfusion CMR". The overall goal of this study is to investigate the signal intensity and relaxation rate characteristics of gadoterate meglumine (Dotarem, Guerbet, USA) enhanced myocardium during rest and stress perfusion cardiovascular magnetic resonance (CMR) compared to gadobutrol (Gadavist) to prove that Dotar...

What is the current status of trial NCT03937921?

This trial is currently completed. The enrollment target is 90 participants. The study started on 2019-07-03. Estimated completion is 2024-10-31.

What interventions are being tested in trial NCT03937921?

The interventions under investigation include: Gadavist 15Ml Solution for Injection (DRUG).

Who is sponsoring clinical trial NCT03937921?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.